A phase II, multicenter, open-label, clinical and pharmacokinetic study of Aplidin [plitidepsin] as a 3-hour infusion every 2 weeks, in relapsing or refractory patients with androgen-independent prostate adenocarcinoma

Trial Profile

A phase II, multicenter, open-label, clinical and pharmacokinetic study of Aplidin [plitidepsin] as a 3-hour infusion every 2 weeks, in relapsing or refractory patients with androgen-independent prostate adenocarcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Plitidepsin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 27 Oct 2008 New source identified and integrated (ClinicalTrials.gov record NCT00780975).
    • 27 Oct 2008 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov. The trial was terminated due to poor accrual.
    • 10 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top